reference population. Growth at 1 and 6 years and school progression at 11 years were similar to those of the reference population. Conclusion: Ectopy is the commonest cause of CH. Children with CH treated early with a mean levothyroxine dose of 11.4 μg/kg/day had a median TSH of 3.07 mU/l at 1 month of age and normal growth.
Introduction
Congenital hypothyroidism (CH) is the most frequent congenital endocrine disorder and is one of the commonest causes of preventable intellectual disability [1] . The prevalence of CH is about one in 2,000-3,000 newborn infants in industrialized countries, depending on the ascertainment method [2] .
Approximately two thirds of CH cases are secondary to developmental abnormalities of the thyroid gland (called thyroid dysgenesis), leading to ectopic, absent or normally shaped and located but hypoplastic thyroid.
The pathogenesis of thyroid dysgenesis likely involves both Mendelian and non-Mendelian mechanisms: the disease is generally sporadic but familial cases occur more often than by chance [3] , while monozygotic twins are almost always discordant [4] . Germline mutations in genes involved in thyroid organogenesis (PAX8 , TTF-1 , TTF-2 and TSHR) are rarely found in thyroid dysgenesis [5, 6] . The remaining one third of CH cases is due to functional disorders with an orthotopic gland. Among these, dyshormonogenesis is usually associated with the development of goiter and classically results from a defect in iodine organification, thyroglobulin (Tg) synthesis or iodide transport. This condition is inherited in an autosomal recessive mode. Finally, some patients present with CH and a normal orthotopic thyroid gland of unknown etiology or rarely due to thyroid-stimulating hormone (TSH) resistance at the receptor level or in its signaling pathway [7] .
The present study was carried out to analyze the initial and final etiological diagnosis of patients with positive TSH neonatal screening followed at our institution. The second purpose of this paper was to evaluate the initial treatment, growth and school progression of these patients.
Methods
We reviewed the medical records of all patients treated for CH between November 1978 and June 2014 at our institution.
Screening for CH was introduced in the late 1970s in Belgium and is carried out on a dried blood spot collected on filter paper between 3 and 5 days after birth. During the study period, two techniques for TSH assay were used. Until December 2007, TSH was measured by radioimmunoassay. If the TSH level was >20 mU/l of whole blood, a second paper was requested. If the TSH was >50 mU/l, the newborn was immediately referred for evaluation and treatment. Until 2009, total thyroxine (T 4 ) was analyzed on the same filter paper. From January 2008, the TSH level was measured by AutoDELFIA automatic immunoassay. The cut-off TSH value was lowered to 15 mU/l to request a second sample of whole blood and to 25 mU/l for urgent referral. The patients with positive screening results were usually seen in our clinic on the day of recall. A family history was obtained and a complete physical examination was performed. The diagnosis was confirmed by both serum TSH and free T 4 assays. Serum Tg levels and TSH receptor autoantibodies were usually measured. Thyroid scintigraphy and ultrasound (US) were carried out to establish the etiology of CH. Epiphyseal maturation was evaluated by X-ray assessment of the knee epiphyseal ossification centers. Levothyroxine ( L -T 4 ) treatment was immediately initiated under the form of an L -T 4 commercial tablet given directly in the newborn's mouth usually without previous crushing.
The patients were classified as having dysgenesis or in situ gland according to the results of imaging studies. Most patients underwent both scintigraphy (with sodium pertechnetate) and US. In cases with discrepancy between the US and the scintiscan, US images were reviewed by an experienced radiologist blinded to the initial imaging diagnosis. Non-thyroidal tissue in the thyroid fossa may be mistaken for a hypoplastic in situ thyroid gland. This entity was defined as bilateral tissue without radioisotope uptake, hyperechogenic and heterogeneous texture, with no true isthmus and with extension around and behind the large cervical blood vessels [8] [9] [10] [11] . Thyroid dysgenesis was further divided into ectopy, athyreosis and in situ hypoplasia. Ectopy was defined as an ectopic thyroid at any point along the pathway of the normal embryological descent from the foramen cecum at the base of the tongue to the thyroid cartilage. Athyreosis was defined by the absence of any detectable thyroid tissue on scintigraphy and on US if available. Athyreosis was subdivided into three groups: apparent athyreosis if Tg was ≥ 2 μg/l, true athyreosis if Tg was <2 μg/l, and indeterminate status if Tg was not measured before L -T 4 treatment onset. Hypoplasia in situ was defined as an in situ gland which was judged small in volume compared to normal newborns [10] . Thyroid dyshormonogenesis was defined as an enlarged in situ gland with abnormally high levels of uptake on radioisotope scan. Normal thyroid was defined as orthotopic gland of normal size and morphology on US and with normal uptake.
A specific genetic diagnosis was searched for in familial or syndromic cases or if consanguinity was reported. The following data were retrospectively recorded from our database: consanguinity, use of assisted reproduction, gestational age, twin pregnancy, mode of delivery, birth weight and length, family history and salient associated medical features. Thyroid hormone and TSH values were collected at screening, at diagnosis and at 1 month of age. Age at treatment initiation, initial L -T 4 dose and age at normalization of TSH levels were studied. For term newborns (>37 weeks), bone age was judged postnatal if distal femoral and proximal tibial ossification points were present. The neonatal auxological data were compared with intergrowth standards [12] while the data at 1 and 6 years of age were compared with British percentiles according to Cole et al. [13] . Age at completion of elementary school was collected for all children older than 11 years. Children were divided into four groups according to school progression (absence of delay in schooling, 1 year delay, more than 2 years delay and special education) and the percentage in each group was compared with statistics of French language schools in Belgium in 1995 [14] .
Statistical analysis was performed with the Graph Pad Prism 6 computer software. Given the non-Gaussian distribution of the data, a non-parametric test (Wilcoxon rank sum test) was used to compare median values. Comparisons of proportions were analyzed by the χ 2 test. Linear and logistic regressions were used to assess trends in the management of CH over the past three decades. The correlations were studied with Pearlman test. Growth data were reported as mean ± standard deviation. A p value ≤ 0.05 was considered statistically significant.
Results
One hundred and sixty-one medical records were reviewed. Patients with transient CH (n = 6, defined as patients with non-increasing L -T 4 requirements with age leading to treatment interruption and normal thyroid function tests thereafter), adopted children who had not undergone neonatal screening and early treatment (n = 5) and those for whom data were insufficient (n = 11) were not included in this study. Hence the study population included 139 subjects ( fig. 1 ).
Thirteen patients were born to consanguineous parents. Regarding clinical features associated with CH, one patient had patent foramen ovale and one had a peripheral pulmonary stenosis which spontaneously resolved. No patient with Down syndrome or another syndromic form of CH was noted. One patient had Hirschprung's disease, one bowel duplication and one kidney duplication. Thyroid imaging allowed to classify the 139 patients into different CH etiologies. Combined scintigraphy and US was performed in 101 patients. This number is positively correlated with the birth year (r 2 = 0.119, p < 0.0001). Discrepancy between US and scintigraphy was noted in 28 cases, with US revealing orthotopic thyroid tissue with no uptake on scintigraphy. Fifteen of those US were recently reviewed by a blinded experienced radiologist according to published imaging features [8, 15] . In 14/15 US, the structures seen in the thyroid fossa did not, upon revision, resemble a thyroid because of lack of a measurable isthmus (n = 14), absence of well-defined outlines (n = 14), extension of tissue behind the great vessels of the neck (n = 10) and heterogeneous pattern (n = 10). One patient had no technetium uptake despite an orthotopic, albeit hypoplastic gland, and the final diagnosis was a homozygous inactivating mutation in TSHR [5] . The etiological diagnosis was reached with US only for 7 patients (five orthotopic gland, one goiter and one considered as true athyreosis based on the absence of thyroid tissue on US and undetectable Tg). Scintigraphy only was carried out in 29 patients, mainly born before 1995. Two patients with a goiter on clinical examination had no thyroid imaging performed. Table 1 shows the diagnostic breakdown of the entire cohort. Amongst patients with apparent athyreosis, homozygous inactivating mutation of TSHR was identified in four patients, including three siblings born to consanguineous parents. One patient and her mother were diagnosed with a PAX8 mutation causing autosomal dominant transmission of CH with thyroid hypoplasia [6] . Sixty-four patients had ectopy; none of them had a family history of thyroid ectopy despite parental consanguinity in three unrelated patients. Six out of 17 cases with dyshormonogenesis (including three siblings) had consanguineous parents. Two patients with Pendred syndrome had a goiter and congenital sensorineural hearing loss, inherited in an autosomal recessive mode [16] . Orthotopic gland with normal size was described in 11 cases. No consanguinity was noticed. Among them, three first cousins were considered as part of the entity of autosomal dominant resistance to TSH [17] . Figure 2 shows the etiological diagnosis according to study period. There does not seem to be a major change in etiological distribution over time. The patients with dyshormonogenesis are numerous before 2007 because of two consanguineous families with three affected siblings each. Table 2 shows gestational, birth and auxological data of the cohort in comparison with the normal population [12] . Birth weight was 0.19 ± 1.26 in newborns with dysgenesis and 0.13 ± 0.94 in newborns with orthotopic thyroid. The proportion of patients with thyroid dysgenesis born after assisted reproductive technology (ART) after 1992 was five (three with ectopy) out of 76 patients (three patients after in vitro fertilization and two after ovarian stimulation and sperm insemination). In Belgium, 1.5% of all births occurred after ART in 2001 and 3.9% in 2009 [18, 19] . Prolonged gestation (>42 weeks) was observed in 5.8% of CH infants versus 1.5% in the normal population (p < 0.00001) [20] . Table 3 shows the age, TSH and T 4 values at screen- Data are expressed as median (range) or n (%). 1 TSH ≥100 mU/l not diluted was considered as at 101 mU/l for the median measure. 2 Total T 4 analysis on filter paper was not carried out after August 2009. 3 Premature children (gestational age <37 weeks) were excluded. ( table 4 ) . A higher initial L -T 4 daily dose was given to newborns with dysgenesis compared to those with dyshormonogenesis (mean dose 11.7 vs. 10.0 μg/kg, p = 0.02).
Growth
Weight, length/height, head circumference and body mass index at age 1 and 6 years were in the normal range for age ( table 5 ) . Of note, no increased incidence of overweight/obesity was noted.
Schooling
Among 52 children aged >11 years, the proportion of children completing primary school at 11 years of age was similar to that of the reference population (78.8 vs. 75.7%, p = 0.78). Those with delayed school progression or in special education appear to have had severer CH and later TSH normalization, but their numbers are too small for statistical analysis ( table 6 ) . Of note, 6/10 patients with markedly delayed school progression (>2 years delay or special education not related to hearing deficit) were siblings from two consanguineous families with autosomal recessive forms of CH. Three patients needed special education due to hearing deficit, two with Pendred syndrome and one with global developmental delay due to 28 weeks prematurity.
Discussion
In the present retrospective observational study, we show that the commonest cause of CH is ectopy and that the proportion of athyreosis versus ectopy has not changed over time, in spite of having halved the TSH threshold for recall in 2007. In addition, we show that children treated at a median age of 11 days with a mean L -T 4 dose of 11.4 μg/kg/day had a median TSH of 3.07 mU/l at 1 month of age and grow and progress in primary school as do the children from the general population. Earlier commencement of adequate thyroid hormone replacement therapy and faster normalization of TSH values were observed over the study period of 36 years. Earlier initiation of L -T 4 treatment over time is reported as very important for normal growth and neurologic development [21] . In the literature, treatment onset differs according to the cohort and the study period. Compared to other cohorts, our results of a mean age at treatment onset of 11 days are very satisfactory [22] [23] [24] [25] [26] . Recommendations for initial L -T 4 dose have evolved over time. During the first decade after the introduction of neonatal screening, the recommended L -T 4 dose was 6-8 μg/kg/day. Since the beginning of the 1990s, it increased to 10-15 μg/ kg/day. Nevertheless, in our institution, the mean L -T 4 dose was already 10 μg/kg/day in the early years of CH [9] . Knowing the precise etiological diagnosis of a CH patient might have implications for the L -T 4 dosage. Previous studies using a variable initial dose strategy according to CH etiology showed rapid normalization of thyroid function without persistent hyperthyroxinemia [27] . Indeed, in our cohort the L -T 4 dose prescribed initially was higher in case of more delayed bone age, which means that clinicians adapted the L -T 4 dose to the severity of CH. Furthermore, the etiological diagnosis allows to correctly inform the parents about the mode of inheritance and the need for lifelong L -T 4 substitution or rather reassessment of thyroid function after the age of 3 years [28] [29] [30] .
In our study, the proportion of CH subtypes (dysgenesis versus normally located gland) was similar to that described in the literature (80 vs. 20%) [7] . As previously reported [31] , a few monogenic defects in candidate genes result in thyroid dysgenesis. Here, we identified three cases with a positive family history among patients with thyroid dysgenesis: a homozygous mutation in TSHR in two consanguineous families transmitted in an autosomal recessive manner [5] and a PAX8 mutation in a mother and her daughter (autosomal dominant mode of inheritance) [6] . Among CH patients with dyshormonogenesis, a high proportion were from consanguineous pedigrees and multiple affected siblings were observed, as described in autosomal recessive diseases. Our observation is consistent with previous studies that suggested a female preponderance for dysgenesis, especially ectopy [32] . In addition, the female predominance is more marked for ectopy than for athyreosis, perhaps suggesting a different mode of inheritance [32] .
We found a relatively high proportion of ART pregnancies compared to the general population among CH patients with dysgenesis. This needs to be confirmed in larger cohorts. This study confirms that patients with athyreosis have a severer clinical picture (higher TSH, lower total T 4 at screening and free T 4 at diagnosis, delayed skeletal maturation at birth). Nevertheless, our study did not reveal any difference in the biochemical severity of CH between boys and girls affected by dysgenesis, as found by Eugène et al. [33] . This might be due to the limited size of our cohort. Also in agreement with previous studies [34] , our results indicate that adequately treated CH patients grow within the normal range and do not present overweight or obesity. We found the previously reported neonatal macrocephaly [35] and high birth weight [36] .
The developmental outcome of CH children treated early remains controversial. Several studies on cognitive function have shown normal development during childhood in most CH patients with good adequacy of treatment [24] . On the other hand, a Swiss study has shown that full-scale intelligence quotients at 14 years of age were within the normal range in the CH group, but lower than in the control group (mean difference of 9.7 after adjusting for sex and socioeconomic status) [25] . Moreover, Kempers et al. [37] demonstrated in a Dutch cohort that cognitive and motor deficits persist in young adults treated early for CH. Another Dutch study [38] reported a lower intelligence quotient at 11 years of age in case of overtreatment defined by free T 4 dosage, but not by TSH dosage. That study has not been confirmed so far. Our results regarding school delay at 11 years of age suggest that primary school progression is normal in adequately treated CH children. These data is very valuable for counselling the parents of an affected child at the moment of diagnosis. A limitation of the current study is that our results were not adjusted for the socio-educational status of the parents, but there is no indication that CH preferentially affects children from families of high or low socio-educational status.
We did not find an increase in congenital malformations as suggested by others. This might be explained by the fact that there were no complex syndromes or chromosomal aneuploidies in our cohort [32, 39] .
In conclusion, our results document that ectopy is the commonest cause of CH. They also document normal growth, normal body mass index and school progression among CH children treated at 11 days of age with 11.4 μg/ kg/day of L -T 4 and followed up at a single center.
